Ending HIV: At the Crossroads of Innovation and Delivery
May 16–19, 2027 | Fairmont Hotel Vancouver, Vancouver, BC, Canada
Scientific Organizers:
Julie Ake, Esper Georges Kallas, Darrell J. Irvine, and Jeff Murry
×
-
May 16–19, 2027 | Fairmont Hotel Vancouver, Vancouver, BC, Canada
Scientific Organizers: Julie Ake, Esper Georges Kallas, Darrell J. Irvine, and Jeff Murry
Julie Ake, MD
Walter Reed Army Institute of Research
Julie A. Ake, M.D., M.Sc., is the Director of the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research, where she oversees the organization's HIV vaccine and cure research portfolios as well as its implementation of the President's Emergency Plan for AIDS Relief. An infectious diseases specialist, she leads international clinical trials and cohorts evaluating vaccines, monoclonal antibodies, combination immunotherapy, and HIV service delivery, currently working across eleven countries in Africa, Asia, and the Americas. She is Co-PI of the MHRP Clinical Trials Unit in the HVTN and ACTG networks and founding Chair of the African Cohort Study (AFRICOS). She is a Fellow of the American College of Physicians and a member of the Alpha Omega Alpha medical honor society. She has organized multiple scientific events including three Early Career Investigator Showcases.
Esper Georges Kallas, PhD
University of São Paulo
Darrell J. Irvine, PhD
Scripps Research Institute
Darrell Irvine, Ph.D., is a Professor at the Scripps Research Institute, where he recently relocated after 20 years as a faculty member at the Massachusetts Institute of Technology, and an Investigator at the Howard Hughes Medical Institute. His research is focused on the application of engineering tools to problems in cellular immunology and the development of new materials for vaccine and drug delivery. Major efforts of the laboratory are directed toward vaccine development for HIV and cancer immunotherapy. His work has been recognized by numerous awards, including election as a Member of the National Academy of Medicine, Fellow of the Biomedical Engineering Society, and Fellow of the American Institute for Medical and Biological Engineering. He has extensive prior experience in organizing scientific conferences, including a previous Keystone Symposia meeting on Engineering Cell Fate and Function.
Jeff Murry, PhD
Gilead Sciences
Jeff Murry, Ph.D., is the Director of HIV Cure Research at Gilead Sciences, where he oversees the discovery of novel therapeutics designed to achieve long-term HIV control in the absence of therapy. His research has spanned diverse approaches across the HIV field, including activating latent HIV reservoirs, recruiting and modulating immune-based effectors that target HIV-infected cells, and mechanisms of intrinsic cell death pathways within HIV-infected cells. He has led teams that have designed and clinically advanced novel small molecule-based approaches, protein-based therapeutics, and therapeutic vaccines. He has worked at Gilead and through external collaborations to build interdisciplinary teams that foster innovation focused on addressing unmet medical needs for people living with HIV.
Available Formats:
Supported by:
Livestream
In Person
On Demand
***Meeting program subject to change.
Available Formats: = Livestream = In Person = On DemandMerchandise Options
Registration Options
Sunday, May 16, 2027
Fundraising
Booking Function
Registration
4:00–8:00 PM
British/Columbia Foyer
Welcome Mixer
6:00–8:00 PM
British/Columbia Foyer
Monday, May 17, 2027
Breakfast
7:30–8:30 AM
Pacific Ballroom, Vancouver Island Room
Welcome Remarks (Joint)
8:30–8:40 AM
British/Columbia Ballroom
Keynote Address (Joint)
8:40–9:30 AM
British/Columbia Ballroom
Michel C. Nussenzweig, HHMI/Rockefeller University
Immune Strategies to Combat Infectious Diseases: What Works and What Doesn't
Immune Strategies to Combat Infectious Diseases: What Works and What Doesn't
Transformative Technologies for Infectious Disease Therapeutics and Vaccines (Joint)
9:30–11:45 AM
British/Columbia Ballroom
Debora Marks, Harvard Medical School
Beating Viruses at their Own Game
Beating Viruses at their Own Game
Kevin Wiehe, Duke University
Mutation Guided Immunogen Design
Mutation Guided Immunogen Design
Pamela J Bjorkman, California Institute of Technology
Structure based Vaccine Design
Structure based Vaccine Design
Darrell J. Irvine, Scripps Research Institute
Harnessing Novel Vaccine Dosing and Adjuvant Strategies
Harnessing Novel Vaccine Dosing and Adjuvant Strategies
Short Talk(s) Chosen from Abstracts
Coffee Break
10:00–10:20 AM
British/Columbia Foyer
Panel Discussion: Vaccine Hesitancy and Distrust (Joint)
11:55–12:55 PM
British/Columbia Ballroom
Poster Setup
12:30–1:00 PM
Pacific Ballroom, Vancouver Island Room
On Own for Lunch
12:55–2:30 PM
Poster Viewing
1:00–10:00 PM
Pacific Ballroom, Vancouver Island Room
Symposia Spotlight 1: Monoclonal Antibody Focus - Prevention or Cure Indications: Multi-Specific Antibodies, mAb Escape
2:30–4:30 PM
Columbia Ballroom
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
British/Columbia Foyer
Emerging Cure Concepts
5:00–7:00 PM
Columbia Ballroom
Thumbi Ndung'u, University of KwaZulu-Natal
HIV Cure Strategies for the Global South
HIV Cure Strategies for the Global South
David D Ho, Aaron Diamond AIDS Research Center (ADARC), Columbia University Medical Center
Novel Small Molecules for Cure
Novel Small Molecules for Cure
Lishomwa C Ndhlovu, Weill Cornell Medicine
Transcriptional Silencing to Advance Remission
Transcriptional Silencing to Advance Remission
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Pacific Ballroom, Vancouver Island Room
Poster Session 1
7:30–10:00 PM
Pacific Ballroom, Vancouver Island Room
Tuesday, May 18, 2027
Breakfast
7:30–8:30 AM
HIV Preclinical Pipeline Progress
8:30–11:30 AM
Columbia Ballroom
Raiees A Andrabi, University of Pennsylvania
Broad HIV Neutralization by Targeted Sequential Vaccination
Broad HIV Neutralization by Targeted Sequential Vaccination
Nicole A Doria-Rose, NIAID, National Institutes of Health
High throughput Monoclonal Antibody Discovery
High throughput Monoclonal Antibody Discovery
Mohamad-Gabriel Alameh, Children's Hospital of Philadelphia
Optimizing mRNA Vaccines for Cure and Preventive Indications
Optimizing mRNA Vaccines for Cure and Preventive Indications
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
British/Columbia Foyer
Poster Setup
11:30–1:00 PM
Pacific Ballroom, Vancouver Island Room
On Own for Lunch
11:30–5:00 PM
Poster Viewing
1:00–10:00 PM
Pacific Ballroom, Vancouver Island Room
Career Roundtable (Joint)
3:00–4:30 PM
Columbia Ballroom
Coffee Available
4:30–5:00 PM
British/Columbia Foyer
Frontiers of HIV Cure
5:00–7:00 PM
Columbia Ballroom
Jeff Murry, Gilead Sciences
Novel Therapeutics Designed to Activate and Reduce Latent HIV Reservoirs
Novel Therapeutics Designed to Activate and Reduce Latent HIV Reservoirs
Charity Wambui Kanyoro, Moi University College of Health Sciences
Dual Affinity Re-Targeting Proteins and Latency Reversal
Dual Affinity Re-Targeting Proteins and Latency Reversal
Michael J Peluso, University of California, San Francisco
Emerging Clinical Data: Cytokines and CAR-T Cells in HIV Cure
Emerging Clinical Data: Cytokines and CAR-T Cells in HIV Cure
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Pacific Ballroom, Vancouver Island Room
Poster Session 2
7:30–10:00 PM
Pacific Ballroom, Vancouver Island Room
Wednesday, May 19, 2027
Breakfast
7:30–8:30 AM
Pacific Ballroom, Vancouver Island Room
Clinical Innovation in Immunologic HIV Countermeasures
8:30–11:30 AM
Columbia Ballroom
Margaret J McElrath, Fred Hutchinson Cancer Center
Emerging Data from the HVTN Discovery Medicine Portfolio
Emerging Data from the HVTN Discovery Medicine Portfolio
Julie Ake, Walter Reed Army Institute of Research
Rapidvax: Learning from the Lymph Node
Rapidvax: Learning from the Lymph Node
Esper Georges Kallas, University of São Paulo
Global Health Vaccines: Lessons from Instituto Butantan
Global Health Vaccines: Lessons from Instituto Butantan
Richard M Dunham, ViiV Healthcare
The N6 Clinical Experience
The N6 Clinical Experience
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
British/Columbia Foyer
On Own for Lunch
11:30–2:30 PM
Symposia Spotlight 2: Emerging Data from Vaccine and Cure Phase 1 Clinical Trials: GrAd Vectored HIV Vaccines, T Cell Engagers for Cure
2:30–4:30 PM
Columbia Ballroom
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
British/Columbia Foyer
Wrangling the Reservoir
5:00–6:45 PM
Columbia Ballroom
Nadia R Roan, University of California, San Francisco
The Reservoir across Compartments: Everything Everywhere all at Once
The Reservoir across Compartments: Everything Everywhere all at Once
Amanda M. Brown, Johns Hopkins University School of Medicine
Fundamental Mechanisms Shaping Complex Sex-Dependent Inflammatory and Neuroendocrine Responses in HIV Infection
Fundamental Mechanisms Shaping Complex Sex-Dependent Inflammatory and Neuroendocrine Responses in HIV Infection
Katharine J Bar, University of Pennsylvania
Strategies for Reservoir Reduction: Lessons from the ACTG Cure Portfolio
Strategies for Reservoir Reduction: Lessons from the ACTG Cure Portfolio
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions
6:45–7:00 PM
Columbia Ballroom
Social Hour with Dinner
7:00–8:00 PM
Pacific Ballroom, Vancouver Island Room
Entertainment
8:00–11:00 PM
Thursday, May 20, 2027
Departure
12:00–11:59 PM
Subscribe for Updates